0 CHECKOUT

Iraq Pharmaceuticals and Healthcare Report Q1 2016

  • ID: 3526581
  • January 2016
  • Region: Iraq
  • 67 pages
  • Business Monitor International
1 of 4

FEATURED COMPANIES

  • Awamedica
  • Ninewa
  • Samarra
  • MORE

Iraq's pharmaceutical market will remain unattractive for multinational drugmakers over the medium term. The government is devoting a greater proportion of fiscal resources to strengthen Iraq's political and economic institutions, which are currently under an immense threat of collapse. This reflects volatile oil prices and the growing threat of Islamic State. This situation has created severe funding shortages to Iraq's healthcare sector, and many donor-funded health programmes have been forced to close, leaving a large number of citizens without access to urgently needed health services and medicines.

Headline Expenditure Projections
- Pharmaceuticals: IQD1.89trn (USD1.59bn) in 2014 to IQD2.02trn (USD1.67bn) in 2015; +6.6% in local currency and +4.6% in US dollar terms. Forecast revised downwards from last quarter due to the availability of new trade data.

- Healthcare: IQD13.15trn (USD11.07bn) in 2014 to IQD13.98trn (USD11.54bn) in 2015; +6.3% in local currency and +4.2% in US dollar terms. Forecast revised downwards slightly from last quarter.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Awamedica
  • Ninewa
  • Samarra
  • MORE

Table: Headline Pharmaceuticals & Healthcare Forecasts (Iraq 2013-2019)

SWOT

Industry Forecast

Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Iraq 2013-2019)

Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Iraq 2013-2019)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Iraq 2013-2019)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Iraq 2013-2019)

Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecasts (Iraq 2013-2019)
Table: Pharmaceutical Trade Data And Forecasts Local Currency (Iraq 2013-2019)

Industry Risk/Reward Index

Middle East and Africa Risk/Reward Index - Q1 2016

Iraq Risk/Reward Index

Rewards

Risks

Regulatory Review

Regulatory Regime

Intellectual Property Issues

Pricing Regime

Reimbursement Regime

Market Overview

Healthcare Sector
Table: Healthcare Resources (Iraq 2009-2014)
Table: Healthcare Personnel (Iraq 2009-2014)
Table: Healthcare Activity (Iraq 2009-2014)

Research & Development

Clinical Trials

Epidemiology

Healthcare Infrastructure

Competitive Landscape

Latest Company Developments
Table: Multinational Market Activity

Generic Drugmakers

Pharmaceutical Distribution

Pharmaceutical Retail Sector

Company Profile

Samarra

Ninewa

Awamedica

Demographic Forecast
Table: Population Headline Indicators (Iraq 1990-2025)
Table: Key Population Ratios (Iraq 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Iraq 1990-2025)
Table: Population By Age Group (Iraq 1990-2025)
Table: Population By Age Group % (Iraq 1990-2025)

Glossary

Methodology

Pharmaceutical Expenditure Forecast Model

Healthcare Expenditure Forecast Model

Notes On Methodology

Risk/Reward Index Methodology

Index Overview
Table: Pharmaceutical Risk/Reward Index Indicators

Indicator Weightings

Note: Product cover images may vary from those shown
3 of 4

Samarra
Ninewa
Awamedica

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Pfizer Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S